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If there is one cancer signalling pathway
that Gut readers should be comfortable
with, it is the Wnt pathway. Central to this
pathway is the adenomatous polyposis coli
(APC) gene responsible for familial adeno-
matous polyposis. Identification of the
APC gene in 1991 heralded the start of an
ongoing period of exponential growth in
our understanding of the molecular basis
of cancer, particularly of the large bowel.
Clinicians can perhaps be forgiven for
finding the ever-expanding list of genes
and interacting pathways with their inac-
cessible names and acronyms daunting.
For many, the paper in this issue by Elvira
Bakker and coworkers at the Netherlands
Cancer Institute revealing the detailed role
of RSPO3 in colorectal carcinogenesis may
only serve to widen the expanding clini-
cian–researcher divide. However, those
brave enough to dive deeper into this
paper will be rewarded with an insight
into the current state of the art of molecu-
lar research into colorectal cancer with an
intriguing mix of confirmation of what we
thought we knew and findings that chal-
lenge previous assumptions.
R-spondin 3 (RSPO3) is a secreted
protein that acts to potentiate Wnt signal-
ling. RSPOs first attracted attention as being
specific ligands of the LGR5 (leucine-rich
repeat-containing G-protein-coupled recep-
tor 5) receptor. LGR5 is the marker for
intestinal stem cells first described by Hans
Clevers. LGR5 was itself identified in a
screen for Wnt pathway targets in the intes-
tine. So in a sense we have come full circle
investigating a ligand, RSPO3, which
impacts on the quintessential colon cancer
pathway, the Wnt pathway, and itself dis-
covered through a detailed investigation of
Wnt signalling. But why investigate a ligand
that is seemingly once removed from the
action? For biologists, the mountaineers’
adage ‘because it’s there’ might suffice, but
Gut readers will ask how is this likely to
impact clinical practice?
RSPO-activating translocation mutations
have been recently found in around 10%
of human colorectal cancers1 and these
tumours respond to RSPO-neutralising
antibodies.2 RSPO3 mutations occur
mutually exclusive with other classical
Wnt-activating mutations (eg, in APC or
CTNNB1 (the gene for β-catenin)), sug-
gesting that RSPO3 mutations can substi-
tute for them with a similar net effect on
Wnt signalling and oncogenesis.
Furthermore, RSPO may potentially repre-
sent a handle by which to pharmacologi-
cally target the notoriously ‘undruggable’
Wnt pathway.3 The problem with the Wnt
pathway itself is that it is corrupted by
pathway-activating mutations downstream
of the Wnt ligands and receptors. Most
successful molecularly targeted therapies
to date have been aimed at ligands or their
receptors. The mutated intracellular signal
transduction elements of the pathway such
as APC and β-catenin are tricky therapeutic
targets. Recent work in a broader array of
tumour types suggests that an RSPO-based
therapy may have a bright future.4
Further tantalising insights come from
the analysis of serrated polyps. The most
aggressive colorectal cancers develop from
serrated polyps via the serrated pathway5
and follow a different molecular chain of
events than the classical Vogelstein
adenoma-to-carcinoma molecular model,
with no classical Wnt pathway mutations.
Late recognition of serrated polyps and
familial forms of serrated polyposis has
meant that molecular understanding of the
serrated pathway lags behind that of classi-
cal adenomas. RSPO3-activating mutations
have recently been found to occur very fre-
quently (30%) in serrated polyps.6 Could
this explain their aggressive nature?
What have the Dutch researchers done?
Using advanced genetically modified
mouse models, they have ensured that
mice, after receiving tamoxifen, express
large amounts of RSPO3 specifically in
stem cells thereby mimicking the effects of
the human RSPO3 mutations. Within only
2 months, these mice develop dramatic
changes in their intestine with widespread
hyperplasia and grossly disrupted crypt-
villus architecture. They do not use the
term ‘serrated’. However, the morphologi-
cal characteristics of serrated architecture
have not been clearly defined in animal
models7 and agreement among patholo-
gists is poor even in human lesions.8 The
mice also develop multiple adenomas and
even invasive carcinomas, something that
is rarely seen in mice where only a single
gene is altered. Intriguingly, the expected
high levels of Wnt pathway activity were
absent as judged by nuclear accumulation
of β-catenin. A further analysis using RNA
sequencing confirmed only modest
increases in Wnt signalling-related genes.
While perhaps unexpected, this would fit
well with the previous evidence published
in Gut that there is a subtle relationship
between levels of Wnt signalling and polyp
development.9 More Wnt signalling does
not translate directly into more polyps and
cancer. The lower levels of Wnt signalling
induced by RSPO3-activating transloca-
tions may be ‘just right’ in this respect.
Does this mean that therapeutic efforts to
lower Wnt signalling could have unex-
pected adverse effects?
The paper goes on to use lineage-
tracing methods to assess which cells turn
into the polyps and cancers they find. By
expressing RSPO3 specifically in stem
cells, one might expect expansion of the
stem cell pool and that polyps and cancers
also arise from these cells. Surprisingly,
there was little expansion of the stem cell
compartment in contrast to the traditional
APC-mutant models.9 RSPO3 seems to act
predominantly on non-stem cells in the
intestine via an alternative more widely
expressed receptor, LGR4. The final sur-
prise is the effect of adding in mutant
KRAS on top of increased RSPO3. In
human tumours, mutations in RSPO3 are
always found in conjunction with KRAS
or BRAF mutations. The KRAS mutations
have been added on top of multiple other
single colorectal cancer gene manipula-
tions in mice (APC, TGFBRII, PTEN and
CDKN2A) and consistently lead to a more
aggressive phenotype.10 It would there-
fore be expected that the addition of a
KRAS mutation would increase the
number of invasive tumours. However,
this was not seen. What is apparent is that
RSPO3 and KRAS show additive effects as
far as the hyperplastic phenotype is
concerned.
In summary, this paper confirms RSPO
as an important driver mutation in color-
ectal cancer and as such it represents an
attractive target for new therapies.
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